

# Glenn W Kaatz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/103893/publications.pdf>

Version: 2024-02-01

101  
papers

6,030  
citations

43973

48  
h-index

76769

74  
g-index

102  
all docs

102  
docs citations

102  
times ranked

4950  
citing authors

#	ARTICLE	IF	CITATIONS
1	Modulation of the Drug Resistance by <i>Platonia insignis</i> Mart. Extract, Ethyl Acetate Fraction and Morelloflavone/Volkensiflavone (Biflavonoids) in <i>Staphylococcus aureus</i> Strains Overexpressing Efflux Pump Genes. <i>Current Drug Metabolism</i> , 2021, 22, 114-122.	0.7	9
2	2-Phenylquinoline <i>S. aureus</i> NorA Efflux Pump Inhibitors: Evaluation of the Importance of Methoxy Group Introduction. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 7827-7848.	2.9	46
3	Studies on 2-phenylquinoline <i>Staphylococcus aureus</i> NorA efflux pump inhibitors: New insights on the C-6 position. <i>European Journal of Medicinal Chemistry</i> , 2018, 155, 428-433.	2.6	19
4	Pharmacophore-Based Repositioning of Approved Drugs as Novel <i>Staphylococcus aureus</i> NorA Efflux Pump Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 1598-1604.	2.9	59
5	Improved Potency of Indole-Based NorA Efflux Pump Inhibitors: From Serendipity toward Rational Design and Development. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 517-523.	2.9	33
6	Searching for Novel Inhibitors of the <i>S. aureus</i> NorA Efflux Pump: Synthesis and Biological Evaluation of the 3-Phenyl-1,4-benzothiazine Analogues. <i>ChemMedChem</i> , 2017, 12, 1293-1302.	1.6	28
7	Fluoroquinolone Resistance in Bacteria. , 2017, , 245-263.		3
8	The "racemic approach" in the evaluation of the enantiomeric NorA efflux pump inhibition activity of 2-phenylquinoline derivatives. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 129, 182-189.	1.4	14
9	Efavirenz-Associated Urinary Matrix Stone—A Rare Presentation. <i>American Journal of the Medical Sciences</i> , 2016, 351, 213-214.	0.4	5
10	Multidrug efflux pumps of Gram-positive bacteria. <i>Drug Resistance Updates</i> , 2016, 27, 1-13.	6.5	171
11	Benzocyclohexane oxide derivatives and neolignans from <i>Piper betle</i> inhibit efflux-related resistance in <i>Staphylococcus aureus</i> . <i>RSC Advances</i> , 2016, 6, 43518-43525.	1.7	17
12	Inhibition of the NorA multi-drug transporter by oxygenated monoterpenes. <i>Microbial Pathogenesis</i> , 2016, 99, 173-177.	1.3	36
13	Indole Based Weapons to Fight Antibiotic Resistance: A Structure-Activity Relationship Study. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 867-891.	2.9	64
14	A Mass Spectrometry-Based Assay for Improved Quantitative Measurements of Efflux Pump Inhibition. <i>PLoS ONE</i> , 2015, 10, e0124814.	1.1	53
15	Clonal relatedness is a predictor of spontaneous multidrug efflux pump gene overexpression in <i>Staphylococcus aureus</i> . <i>International Journal of Antimicrobial Agents</i> , 2015, 45, 464-470.	1.1	12
16	Mutations within the <i>mepA</i> Operator Affect Binding of the MepR Regulatory Protein and Its Induction by MepA Substrates in <i>Staphylococcus aureus</i> . <i>Journal of Bacteriology</i> , 2015, 197, 1104-1114.	1.0	8
17	Analyses of Multidrug Efflux Pump-Like Proteins Encoded on the <i>Staphylococcus aureus</i> Chromosome. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 747-748.	1.4	34
18	Role of Multidrug Efflux Pumps in Gram-Positive Bacteria. , 2014, , 275-285.		1

#	ARTICLE	IF	CITATIONS
19	Structural mechanism of transcription regulation of the <i>Staphylococcus aureus</i> multidrug efflux operon <i>mepRA</i> by the MarR family repressor MepR. <i>Nucleic Acids Research</i> , 2014, 42, 2774-2788.	6.5	35
20	Antimicrobial Salvage Therapy for Persistent Staphylococcal Bacteremia Using Daptomycin Plus Ceftaroline. <i>Clinical Therapeutics</i> , 2014, 36, 1317-1333.	1.1	151
21	A new plant-derived antibacterial is an inhibitor of efflux pumps in <i>Staphylococcus aureus</i> . <i>International Journal of Antimicrobial Agents</i> , 2013, 42, 513-518.	1.1	62
22	Evaluation of Daptomycin Non-Susceptible <i>Staphylococcus aureus</i> for Stability, Population Profiles, <i>mprF</i> Mutations, and Daptomycin Activity. <i>Infectious Diseases and Therapy</i> , 2013, 2, 187-200.	1.8	9
23	Mutagenesis and Modeling To Predict Structural and Functional Characteristics of the <i>Staphylococcus aureus</i> MepA Multidrug Efflux Pump. <i>Journal of Bacteriology</i> , 2013, 195, 523-533.	1.0	27
24	Inhibition of drug efflux pumps in <i>Staphylococcus aureus</i> : current status of potentiating existing antibiotics. <i>Future Microbiology</i> , 2013, 8, 491-507.	1.0	94
25	Re-evolution of the 2-Phenylquinolines: Ligand-Based Design, Synthesis, and Biological Evaluation of a Potent New Class of <i>Staphylococcus aureus</i> NorA Efflux Pump Inhibitors to Combat Antimicrobial Resistance. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 4975-4989.	2.9	51
26	The Molecular Mechanisms of Allosteric Mutations Impairing MepR Repressor Function in Multidrug-Resistant Strains of <i>Staphylococcus aureus</i> . <i>MBio</i> , 2013, 4, e00528-13.	1.8	19
27	Alternative Mutational Pathways to Intermediate Resistance to Vancomycin in Methicillin-Resistant <i>Staphylococcus aureus</i> . <i>Journal of Infectious Diseases</i> , 2013, 208, 67-74.	1.9	39
28	Antibacterial Sesquiterpenoid Derivatives from <i>Ferula ferulaeoides</i> . <i>Planta Medica</i> , 2013, 79, 701-706.	0.7	16
29	Functional Consequences of Substitution Mutations in MepR, a Repressor of the <i>Staphylococcus aureus</i> <i>mepA</i> Multidrug Efflux Pump Gene. <i>Journal of Bacteriology</i> , 2013, 195, 3651-3662.	1.0	18
30	Evaluation of Ceftaroline Activity against Heteroresistant Vancomycin-Intermediate <i>Staphylococcus aureus</i> and Vancomycin-Intermediate Methicillin-Resistant <i>S. aureus</i> Strains in an <i>In Vitro</i> Pharmacokinetic/Pharmacodynamic Model: Exploring the "Seesaw Effect". <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 2664-2668.	1.4	54
31	Ligand Promiscuity between the Efflux Pumps Human P-Glycoprotein and <i>S. aureus</i> NorA. <i>ACS Medicinal Chemistry Letters</i> , 2012, 3, 248-251.	1.3	20
32	Expression of multidrug resistance efflux pump genes in clinical and environmental isolates of <i>Staphylococcus aureus</i> . <i>International Journal of Antimicrobial Agents</i> , 2012, 40, 204-209.	1.1	69
33	Pyrazolo[4,3- <i>c</i> ][1,2]benzothiazines 5,5-Dioxide: A Promising New Class of <i>Staphylococcus aureus</i> NorA Efflux Pump Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 3568-3572.	2.9	82
34	Searching for innovative quinolone-like scaffolds: synthesis and biological evaluation of 2,1-benzothiazine 2,2-dioxide derivatives. <i>MedChemComm</i> , 2012, 3, 1092.	3.5	20
35	Mechanisms of in-vitro-selected daptomycin-non-susceptibility in <i>Staphylococcus aureus</i> . <i>International Journal of Antimicrobial Agents</i> , 2011, 38, 442-446.	1.1	49
36	Discovery of Novel Inhibitors of the NorA Multidrug Transporter of <i>Staphylococcus aureus</i> . <i>Journal of Medicinal Chemistry</i> , 2011, 54, 354-365.	2.9	67

#	ARTICLE	IF	CITATIONS
37	Evolution from a Natural Flavones Nucleus to Obtain 2-(4-Propoxyphenyl)quinoline Derivatives As Potent Inhibitors of the <i>S. aureus</i> NorA Efflux Pump. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 5722-5736.	2.9	102
38	Goldenseal ( <i>Hydrastis canadensis</i> L.) Extracts Synergistically Enhance the Antibacterial Activity of Berberine via Efflux Pump Inhibition. <i>Planta Medica</i> , 2011, 77, 835-840.	0.7	74
39	Characterizing Vancomycin-Resistant Enterococcus Strains with Various Mechanisms of Daptomycin Resistance Developed in an <i>In Vitro</i> Pharmacokinetic/Pharmacodynamic Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 4748-4754.	1.4	21
40	From 6-Aminoquinolone Antibacterials to 6-Amino-7-thiopyranopyridinylquinolone Ethyl Esters as Inhibitors of <i>Staphylococcus aureus</i> Multidrug Efflux Pumps. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 4466-4480.	2.9	41
41	Ethidium Bromide MIC Screening for Enhanced Efflux Pump Gene Expression or Efflux Activity in <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 5070-5073.	1.4	84
42	Evaluation of dalbavancin, tigecycline, minocycline, tetracycline, teicoplanin and vancomycin against community-associated and multidrug-resistant hospital-associated methicillin-resistant <i>Staphylococcus aureus</i> . <i>International Journal of Antimicrobial Agents</i> , 2010, 35, 25-29.	1.1	18
43	In silico genetic correlations of multidrug efflux pump gene expression in <i>Staphylococcus aureus</i> . <i>International Journal of Antimicrobial Agents</i> , 2010, 36, 222-229.	1.1	14
44	Treatment strategies for infective endocarditis. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 345-360.	0.9	13
45	Structural and biochemical characterization of MepR, a multidrug binding transcription regulator of the <i>Staphylococcus aureus</i> multidrug efflux pump MepA. <i>Nucleic Acids Research</i> , 2009, 37, 1211-1224.	6.5	52
46	Impact of Inoculum Size and Heterogeneous Vancomycin-Intermediate <i>Staphylococcus aureus</i> (hVISA) on Vancomycin Activity and Emergence of VISA in an <i>In Vitro</i> Pharmacodynamic Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 805-807.	1.4	29
47	Inability of a reserpine-based screen to identify strains overexpressing efflux pump genes in clinical isolates of <i>Staphylococcus aureus</i> . <i>International Journal of Antimicrobial Agents</i> , 2009, 33, 360-363.	1.1	29
48	Fluoroquinolone Resistance in Bacteria. , 2009, , 195-205.		3
49	Synthesis and evaluation of fluoroquinolone derivatives as substrate-based inhibitors of bacterial efflux pumps. <i>European Journal of Medicinal Chemistry</i> , 2008, 43, 2453-2463.	2.6	66
50	Synthesis and evaluation of PSSRI-based inhibitors of <i>Staphylococcus aureus</i> multidrug efflux pumps. <i>Biorganic and Medicinal Chemistry Letters</i> , 2008, 18, 1368-1373.	1.0	38
51	From Phenothiazine to 3-Phenyl-1,4-benzothiazine Derivatives as Inhibitors of the <i>Staphylococcus aureus</i> NorA Multidrug Efflux Pump. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 4321-4330.	2.9	105
52	Inhibitors of Bacterial Multidrug Efflux Pumps from the Resin Glycosides of <i>Ipomoea murucoides</i> . <i>Journal of Natural Products</i> , 2008, 71, 1037-1045.	1.5	79
53	Daptomycin Activity against <i>Staphylococcus aureus</i> following Vancomycin Exposure in an <i>In Vitro</i> Pharmacodynamic Model with Simulated Endocardial Vegetations. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 831-836.	1.4	80
54	Multidrug efflux pump overexpression in <i>Staphylococcus aureus</i> after single and multiple <i>in vitro</i> exposures to biocides and dyes. <i>Microbiology (United Kingdom)</i> , 2008, 154, 3144-3153.	0.7	107

#	ARTICLE	IF	CITATIONS
55	Synergy between gemifloxacin and trimethoprim/sulfamethoxazole against community-associated methicillin-resistant <i>Staphylococcus aureus</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 1305-1310.	1.3	19
56	Teicoplanin pharmacodynamics in reference to the accessory gene regulator ( <i>agr</i> ) in <i>Staphylococcus aureus</i> using an in vitro pharmacodynamic model. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 61, 1099-1102.	1.3	9
57	Efflux-Related Resistance to Norfloxacin, Dyes, and Biocides in Bloodstream Isolates of <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 3235-3239.	1.4	179
58	Fluoroquinolone Resistance in <i>Streptococcus pneumoniae</i> : Area Under the Concentration-Time Curve/MIC Ratio and Resistance Development with Gatifloxacin, Gemifloxacin, Levofloxacin, and Moxifloxacin. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 1315-1320.	1.4	29
59	Correlation of vancomycin and daptomycin susceptibility in <i>Staphylococcus aureus</i> in reference to accessory gene regulator ( <i>agr</i> ) polymorphism and function. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 59, 1190-1193.	1.3	29
60	Evaluation of daptomycin treatment of <i>Staphylococcus aureus</i> bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 60, 334-340.	1.3	71
61	The Phenolic Diterpene Totarol Inhibits Multidrug Efflux Pump Activity in <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 4480-4483.	1.4	103
62	Community- and health care-associated methicillin-resistant <i>Staphylococcus aureus</i> : a comparison of molecular epidemiology and antimicrobial activities of various agents. <i>Diagnostic Microbiology and Infectious Disease</i> , 2007, 58, 41-47.	0.8	94
63	N-Caffeoylphenalkylamide derivatives as bacterial efflux pump inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 1755-1758.	1.0	81
64	Antibacterials and modulators of bacterial resistance from the immature cones of <i>Chamaecyparis lawsoniana</i> . <i>Phytochemistry</i> , 2007, 68, 210-217.	1.4	121
65	Antimicrobial Susceptibility and Staphylococcal Chromosomal CassettemecType in Community- and Hospital-Associated Methicillin-Resistant <i>Staphylococcus aureus</i> . <i>Pharmacotherapy</i> , 2007, 27, 3-10.	1.2	29
66	Polyacylated Oligosaccharides from Medicinal Mexican Morning Glory Species as Antibacterials and Inhibitors of Multidrug Resistance in <i>Staphylococcus aureus</i> . <i>Journal of Natural Products</i> , 2006, 69, 406-409.	1.5	99
67	Characteristics of Patients With Healthcare-Associated Infection Due to SCCmecType IV Methicillin-Resistant <i>Staphylococcus aureus</i> . <i>Infection Control and Hospital Epidemiology</i> , 2006, 27, 1025-1031.	1.0	100
68	Mechanisms of daptomycin resistance in <i>Staphylococcus aureus</i> . <i>International Journal of Antimicrobial Agents</i> , 2006, 28, 280-287.	1.1	75
69	MepR, a Repressor of the <i>Staphylococcus aureus</i> MATE Family Multidrug Efflux Pump MepA, Is a Substrate-Responsive Regulatory Protein. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 1276-1281.	1.4	76
70	Multidrug Resistance in <i>Staphylococcus aureus</i> Due to Overexpression of a Novel Multidrug and Toxin Extrusion (MATE) Transport Protein. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 1857-1864.	1.4	241
71	Clinical isolates of <i>Staphylococcus aureus</i> from 1987 and 1989 demonstrating heterogeneous resistance to vancomycin and teicoplanin. <i>Diagnostic Microbiology and Infectious Disease</i> , 2005, 51, 119-125.	0.8	19
72	Effect of Promoter Region Mutations and <i>mgrA</i> Overexpression on Transcription of <i>norA</i> , Which Encodes a <i>Staphylococcus aureus</i> Multidrug Efflux Transporter. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 161-169.	1.4	79

#	ARTICLE	IF	CITATIONS
73	Bacterial efflux pump inhibition. <i>Current Opinion in Investigational Drugs</i> , 2005, 6, 191-8.	2.3	32
74	Catechin Gallates Inhibit Multidrug Resistance (MDR) in <i>Staphylococcus aureus</i> . <i>Planta Medica</i> , 2004, 70, 1240-1242.	0.7	97
75	Effect of substrate exposure and other growth condition manipulations on <i>norA</i> expression. <i>Journal of Antimicrobial Chemotherapy</i> , 2004, 54, 364-369.	1.3	20
76	Antibacterial and resistance modifying activity of. <i>Phytochemistry</i> , 2004, 65, 3249-3254.	1.4	309
77	Inhibitors of multidrug resistance (MDR) have affinity for MDR substrates. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 881-885.	1.0	41
78	Structural differences between paroxetine and femoxetine responsible for differential inhibition of <i>Staphylococcus aureus</i> efflux pumps. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 3093-3097.	1.0	20
79	In vitro activities of mutant prevention concentration-targeted concentrations of fluoroquinolones against <i>Staphylococcus aureus</i> in a pharmacodynamic model. <i>International Journal of Antimicrobial Agents</i> , 2004, 24, 150-160.	1.1	42
80	Structural features of piperazinyl-linked ciprofloxacin dimers required for activity against drug-resistant strains of <i>Staphylococcus aureus</i> . <i>Bioorganic and Medicinal Chemistry Letters</i> , 2003, 13, 2109-2112.	1.0	78
81	Piperazinyl-linked fluoroquinolone dimers possessing potent antibacterial activity against drug-resistant strains of <i>Staphylococcus aureus</i> . <i>Bioorganic and Medicinal Chemistry Letters</i> , 2003, 13, 1745-1749.	1.0	51
82	Phenylpiperidine selective serotonin reuptake inhibitors interfere with multidrug efflux pump activity in <i>Staphylococcus aureus</i> . <i>International Journal of Antimicrobial Agents</i> , 2003, 22, 254-261.	1.1	79
83	Phenothiazines and Thioxanthenes Inhibit Multidrug Efflux Pump Activity in <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 719-726.	1.4	184
84	A novel inhibitor of multidrug efflux pumps in <i>Staphylococcus aureus</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 51, 13-17.	1.3	186
85	Serum Bactericidal Activity of the Methoxyfluoroquinolones Gatifloxacin and Moxifloxacin against Clinical Isolates of <i>Staphylococcus</i> Species: Are the Susceptibility Breakpoints Too High?. <i>Clinical Infectious Diseases</i> , 2003, 37, 1392-1395.	2.9	7
86	Activities of Mutant Prevention Concentration-Targeted Moxifloxacin and Levofloxacin against <i>Streptococcus pneumoniae</i> in an In Vitro Pharmacodynamic Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 2606-2614.	1.4	57
87	Identification and characterization of a novel efflux-related multidrug resistance phenotype in <i>Staphylococcus aureus</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2002, 50, 833-838.	1.3	56
88	Inhibition of bacterial efflux pumps: a new strategy to combat increasing antimicrobial agent resistance. <i>Expert Opinion on Emerging Drugs</i> , 2002, 7, 223-233.	1.0	28
89	Activities of Newer Fluoroquinolones against Ciprofloxacin-Resistant <i>Streptococcus pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 1654-1659.	1.4	44
90	Oxazolidinones: new players in the battle against multi-resistant Gram-positive bacteria. <i>Expert Opinion on Emerging Drugs</i> , 2001, 6, 43-55.	1.1	6

#	ARTICLE	IF	CITATIONS
91	Evidence for the Existence of a Multidrug Efflux Transporter Distinct from NorA in <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 1404-1406.	1.4	125
92	Comparison of a Rabbit Model of Bacterial Endocarditis and an In Vitro Infection Model with Simulated Endocardial Vegetations. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 1921-1924.	1.4	38
93	Introduction of a <i>norA</i> Promoter Region Mutation into the Chromosome of a Fluoroquinolone-Susceptible Strain of <i>Staphylococcus aureus</i> Using Plasmid Integration. <i>Antimicrobial Agents and Chemotherapy</i> , 1999, 43, 2222-2224.	1.4	30
94	Effects of NorA Inhibitors on In Vitro Antibacterial Activities and Postantibiotic Effects of Levofloxacin, Ciprofloxacin, and Norfloxacin in Genetically Related Strains of <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 1999, 43, 335-340.	1.4	117
95	The effects of NorA inhibition on the activities of levofloxacin, ciprofloxacin and norfloxacin against two genetically related strains of <i>Staphylococcus aureus</i> in an in-vitro infection model. <i>Journal of Antimicrobial Chemotherapy</i> , 1999, 44, 343-349.	1.3	32
96	Topoisomerase Mutations in Fluoroquinolone-Resistant and Methicillin-Susceptible and -Resistant Clinical Isolates of <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 1998, 42, 197-198.	1.4	16
97	Efficacy of LY333328 against Experimental Methicillin-Resistant <i>Staphylococcus aureus</i> Endocarditis. <i>Antimicrobial Agents and Chemotherapy</i> , 1998, 42, 981-983.	1.4	60
98	Comparative In Vitro Activities and Postantibiotic Effects of the Oxazolidinone Compounds Eperezolid (PNU-100592) and Linezolid (PNU-100766) versus Vancomycin against <i>Staphylococcus aureus</i> , Coagulase-Negative Staphylococci, <i>Enterococcus faecalis</i> , and <i>Enterococcus faecium</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 1998, 42, 721-724.	1.4	132
99	Efficacy of Trovafloxacin against Experimental <i>Staphylococcus aureus</i> Endocarditis. <i>Antimicrobial Agents and Chemotherapy</i> , 1998, 42, 254-256.	1.4	21
100	Mechanisms of fluoroquinolone resistance in genetically related strains of <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 1997, 41, 2733-2737.	1.4	137
101	The emergence of resistance to ciprofloxacin during treatment of experimental <i>Staphylococcus aureus</i> endocarditis. <i>Journal of Antimicrobial Chemotherapy</i> , 1987, 20, 753-758.	1.3	83